Cover Image
市場調查報告書

膠原酶3:開發中產品分析

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363134
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
膠原酶3:開發中產品分析 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 41 Pages
簡介

本報告提供膠原酶3藥物的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

膠原酶3概要

治療藥的開發

膠原酶3:開發中的產品 - 各開發階段

膠原酶3:開發中的產品 - 治療範圍別

膠原酶3:開發中的產品 - 各適應症

膠原酶3:開發中產品概況

  • 初期階段的產品

膠原酶3:企業開發中的產品

膠原酶3:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

膠原酶3治療藥的開發企業

  • Paradigm Biopharmaceuticals Limited
  • Pfizer Inc.
  • 武田藥品工業

膠原酶3:藥物簡介

膠原酶3:暫停中的計劃

膠原酶3:中止開發的產品

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0598TDB

Summary

Global Markets Direct's, 'Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H2 2016', provides in depth analysis on Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted pipeline therapeutics.

The report provides comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
  • The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Overview
  • Therapeutics Development
    • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Products under Development by Stage of Development
    • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Products under Development by Therapy Area
    • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Products under Development by Indication
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Products under Development by Companies
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
    • Paradigm Biopharmaceuticals Limited
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles
    • Pelladerm - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pentosan polysulfate sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-152 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Projects
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Featured News & Press Releases
    • Sep 16, 2016: Preclinical study underpins efficacy of Paradigms Rhinosul for hay fever treatment
    • Sep 07, 2016: Paradigm's PPS as a potential breakthrough in t he treatment of viral arthritis and joint pain
    • Aug 19, 2016: Market update Paradigm's PPS nasal spray to treat Allergic Rhinitis (Hay Fever)
    • Mar 02, 2016: Paradigm initiates second clinical trial site to investigate ZILOSUL as a treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury
    • Feb 25, 2016: First participant in Paradigm's clinical trial starts ZILOSUL treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury
    • Feb 23, 2016: Paradigm starts clinical trial to investigate ZILOSUL as a treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury
    • Dec 03, 2015: Elite athlete from a major sporting code treated with Paradigm's ZILOSUL under the Therapeutic Goods Administration's Special Access Scheme
    • Nov 23, 2015: Paradigm's ZILOSUL approved for clinical trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016
  • Pipeline by Pfizer Inc., H2 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top